Skip to main content

Pulmonary Embolism

Pulmonary embolism is the most common cause of post-discharge mortality after major pelvic oncology — after radical cystectomy the 30-day VTE rate is 3–10% without extended prophylaxis, and clinically significant PE is disproportionately represented in that number. For the reconstructive urologist, the clinical challenge has two faces: recognizing PE in a postoperative patient whose dyspnea could equally plausibly be atelectasis, pneumonia, fluid overload, or an early anastomotic leak; and delivering therapeutic anticoagulation when the bleed bed is 7 days old. This article covers the evidence-based diagnostic pathway, risk stratification, contemporary treatment, and the peri-surgical decisions that differ from the medical-ICU default.

See also: Antithrombotic Therapy (VTE prophylaxis, reversal, heparin resistance), Cardiovascular Risk, ERAS (extended 4-week prophylaxis after pelvic oncology).

Epidemiology and Pathophysiology​

PE affects approximately 370,000 patients annually in the United States, incidence 60–120 per 100,000 person-years, and causes an estimated 60,000–100,000 deaths per year — the third leading cause of cardiovascular death.[1][2] Incidence rises steeply with age: <50 per 100,000 before age 50, ~350 per 100,000 after age 75.[1] Residual lifetime risk at age 45 is ~8%.[2]

Mechanism. Seventy to eighty percent of PEs originate from lower-extremity and pelvic deep veins; ~6% from upper-extremity veins.[1] Thrombogenesis follows the Virchow triad: venous stasis, hypercoagulability, endothelial injury — all three are operative after major pelvic surgery. Embolized clot elevates pulmonary vascular resistance, raises RV afterload, decreases LV preload, and in large clot burdens precipitates hemodynamic collapse.

Clinical Presentation​

Most common symptoms in unselected PE populations:[1][3][4][5][6]

FeatureFrequency
Dyspnea~80%
Pleuritic chest pain60–70%
Tachycardia65–70%
Hypoxemia~70%
Hemoptysis5–13%
SyncopeLess common but important (0.6–2.2% of syncope admissions have PE at 30 days)
Hemodynamic compromise (shock, hypotension, sudden death)10–20%

Postoperative recognition problem. Dyspnea after cystectomy or open nephrectomy has a broad differential — atelectasis, pneumonia, transfusion-related acute lung injury, volume overload, anastomotic leak with sepsis, and PE all co-occur in this population. The lesson is a low threshold for CTPA in any postoperative patient with unexplained dyspnea, tachycardia, or hypoxemia — especially in days 3–14 after major pelvic oncology when the VTE risk curve peaks.

PE is diagnosed in <10% of patients evaluated for suspected PE[1][3] — the denominator is large for a reason.

Diagnostic Approach​

Clinical Probability Assessment​

Structured scoring outperforms gestalt and is the first step in every guideline-aligned workup.[3][4][5]

Wells Score for PE — original 7-variable version stratifies low / intermediate / high probability; the dichotomized 2-level version bins as PE-unlikely (≤4) vs PE-likely (>4). Validation PE prevalence: 1% low, 16% intermediate, 38% high.[5][11]

Revised Geneva Score — validated alternative incorporating age, active cancer, hemoptysis, previous VTE.[5][11]

PERC (Pulmonary Embolism Rule-Out Criteria) — when all 8 criteria are met in a low-pretest-probability patient, PE can be excluded without further testing:

  • Age <50
  • HR <100
  • SpO₂ >94%
  • No unilateral leg swelling
  • No hemoptysis
  • No recent surgery or trauma
  • No prior VTE
  • No exogenous estrogen use

PERC is endorsed by ASH, NICE, and PERT; ESC/ERS do not recommend PERC due to prevalence concerns in European cohorts.[10][11] For the postoperative urologic patient, PERC is essentially useless — "no recent surgery" fails by definition.

D-Dimer​

Fibrin degradation product; highly sensitive, poorly specific.[1][7][9]

Use D-dimer only for low or intermediate pretest probability.[3][4] High-probability patients proceed directly to imaging.

  • Standard cutoff: <500 ng/mL FEU → PE excluded in low/intermediate probability.
  • Age-adjusted: age × 10 ng/mL FEU for patients ≥50; safely reduces imaging without missing PE.[3][4][8]
  • YEARS algorithm: if none of three YEARS items (clinical DVT signs, hemoptysis, PE most likely diagnosis) → D-dimer cutoff 1,000 ng/mL; if any present → cutoff 500 ng/mL.[3]

Postoperative limitation. D-dimer is elevated in nearly every postoperative patient from surgical inflammation alone — its specificity collapses in the perioperative period, and most prospective D-dimer studies excluded anticoagulated patients.[3][4] In practical terms, D-dimer does not rule out PE in the first 2 weeks after major pelvic surgery.

Imaging​

CTPA is the reference imaging test per ESC/ERS, NICE, and PERT guidelines.[10][11]

V/Q scanning — ASH prefers V/Q when rapidly available to limit radiation; others reserve V/Q for patients with contrast allergy, significant renal impairment, or pregnancy.[10][11]

Lower-extremity duplex ultrasound — reasonable when CTPA/V/Q are infeasible or non-diagnostic, or as an adjunct; detection of DVT confirms the need for anticoagulation regardless of PE imaging findings.[11]

Risk Stratification​

Risk stratification drives treatment intensity and disposition.[3][4]

Hemodynamic Categories​

CategoryDefinition30-day mortality
High-risk (massive)SBP <90 mmHg sustained >15 min, or pressors required, or end-organ hypoperfusion, or cardiac arrest~20%[1]
Intermediate-risk (submassive)Normotensive + RV dysfunction (echo or CT) and/or troponin / BNP elevation2–15%
Low-riskNormotensive, no RV dysfunction, no biomarker elevation<1%

RV dysfunction markers:[1]

  • Echocardiography — RV dilatation, hypokinesis, McConnell sign, septal bowing
  • CT RV:LV ratio >1.0 (83% sensitivity, 75% specificity for echo-defined RV dysfunction)
  • Elevated troponin, BNP, or NT-proBNP

sPESI (Simplified Pulmonary Embolism Severity Index)​

One point each for age >80, history of cancer, chronic cardiopulmonary disease, HR ≥110, SBP <100, SpO₂ <90%.[1]

  • sPESI = 0 → 30-day mortality ~1% → candidate for outpatient management or early discharge.
  • sPESI ≥1 → elevated mortality → inpatient management.

Treatment​

Anticoagulation — the Foundation​

For every hemodynamically stable PE (SBP ≥90 mmHg), anticoagulation is the primary therapy.[3][4][12]

DOACs are first-line for most patients.[13][1][12] Versus heparin/warfarin, DOACs are non-inferior for treating PE and have a ~0.6% lower rate of major bleeding.[1]

FDA-approved DOACs for PE:

AgentLoadingMaintenance
Rivaroxaban15 mg BID × 21 days20 mg daily
Apixaban10 mg BID × 7 days5 mg BID
Edoxaban5–10 d of parenteral AC first60 mg daily
Dabigatran5–10 d of parenteral AC first150 mg BID

Cancer-associated PE — LMWH is historically preferred; DOACs (edoxaban, rivaroxaban, apixaban) are acceptable alternatives except in GI cancers (higher GI bleed signal with DOAC in gastric/colorectal cancer).[12]

Antiphospholipid syndrome — vitamin K antagonists preferred over DOACs (DOACs inferior in triple-positive APS).[12]

Duration​

ScenarioDuration
Provoked PE (major transient risk factor)3 months, then stop
Unprovoked PE, or persistent risk factorExtended / indefinite
Cancer-associated PEExtended (indefinite or until cancer cured)
Extended-phase dosingReduced-dose apixaban 2.5 mg BID or rivaroxaban 10 mg daily after 6 months of therapeutic AC

Thrombolysis​

Indicated for high-risk (massive) PE — SBP <90 mmHg, pressors, or arrest.[3][4][12]

AgentDose
Alteplase (rt-PA) — the standard100 mg IV over 2 h
Reduced-dose alteplase25–50 mg (investigational; PEITHO-3 ongoing)
TenecteplaseStudied in PEITHO; not FDA-approved for PE

Efficacy in high-risk PE. Systemic thrombolysis reduces 30-day mortality by 1.6% absolute (3.9% → 2.3%, OR 0.59).[1]

Bleeding. Major bleeding +1.4%; intracranial hemorrhage 1.7%.[1][3][4] In PEITHO, extracranial bleeding was 6.3% with tenecteplase vs 1.2% with placebo.

Intermediate-risk PE — do NOT routinely thrombolyse.[12] Meta-analysis shows mortality reduction (OR 0.53–0.58) but major bleed increase (OR 2.84–4.6); NNT 59 for death prevented, NNH 78 for intracranial hemorrhage. Reserve thrombolysis for rescue after hemodynamic deterioration.

Postoperative caveat. Recent major surgery (especially cranial, spinal, or major abdominal within 2–4 weeks) is a relative or absolute contraindication to systemic thrombolysis. For the reconstructive urologist, this is the decision that most commonly pushes treatment toward catheter-directed or surgical options.

Catheter-Directed Interventions​

For high-risk PE when systemic thrombolysis is contraindicated (e.g., recent major pelvic surgery) or has failed:[3][4][12]

  • Catheter-directed thrombolysis (CDT) — localized low-dose rt-PA delivery via pulmonary artery catheter; lower systemic bleed risk, particularly relevant in the postoperative patient.
  • Mechanical / aspiration thrombectomy (FlowTriever, Indigo) — no thrombolytic required; attractive option after recent surgery.

Surgical Embolectomy​

Reserved for high-risk PE with contraindications to or failure of thrombolysis, or imminent shock.[2][12] Modern series show improving safety and efficacy, though selection bias toward the sickest patients persists.

ECMO​

Veno-arterial ECMO as a bridge to definitive therapy (thrombectomy, embolectomy) in catastrophic PE with refractory shock or post-arrest.[2][3][4]

Pulmonary Embolism Response Teams (PERT)​

Multidisciplinary teams — pulmonary / vascular medicine, interventional radiology, cardiothoracic surgery, critical care — activated for intermediate-to-high-risk PE to coordinate advanced therapy. Associated with improved utilization of advanced therapies and, in some series, better outcomes.[3][4]

Outpatient Management​

Low-risk PE (sPESI = 0, normotensive, no RV dysfunction, no biomarker elevation) may be treated outpatient or with early discharge if the patient has reliable home support, medication access, and follow-up.[1][12] This is not a typical disposition for the immediate postoperative patient, but is relevant for late-presenting post-discharge PE.

IVC Filters​

IVC filters are NOT recommended in patients who can receive anticoagulation.[12] Reserve for:

  • Absolute contraindications to anticoagulation (active major bleeding, recent cranial or spinal surgery).
  • Recurrent PE despite therapeutic anticoagulation.
  • PE in the early postoperative window where bleeding risk of therapeutic AC is prohibitive and an alternative to anticoagulation is required as a temporizing measure.

If placed, retrieve the filter as soon as anticoagulation becomes safe — permanent filters are associated with IVC thrombosis, filter migration, and late mechanical complications.

The Postoperative Patient — Specific Considerations​

This section is the one that most differs from the medical-ICU default PE pathway.

Anticoagulation Initiation After Recent Surgery​

  • Within 48 h of major pelvic surgery: therapeutic anticoagulation for PE is high-risk for reoperation-level bleeding. Consult surgery before initiating; IVC filter may be temporizing.
  • 48 h – 7 days: decision is case-specific. Therapeutic LMWH or UFH (reversible) is preferred over DOAC in the immediate postoperative window.
  • Beyond 7 days: standard anticoagulation, often transitioning to DOAC.

Thrombolysis After Recent Surgery​

Major surgery within ~2–4 weeks is commonly cited as a contraindication. For high-risk postoperative PE in this window, catheter-directed thrombectomy or surgical embolectomy is preferred over systemic thrombolysis.

Prophylaxis — See Antithrombotic Therapy​

Procedure-specific VTE prophylaxis (including the Tikkinen et al. urologic VTE risk matrix and the 4-week extended LMWH recommendation for pelvic oncology) is covered in the Antithrombotic Therapy article.

Risk Factors​

Strong Transient (Provoked)​

  • Surgery — especially major orthopedic and pelvic oncology (~1% post-op VTE rate even with prophylaxis)
  • Immobilization, hospitalization, paresis
  • Trauma or fracture
  • Active cancer (accounts for ~20% of all VTE)
  • Pregnancy and postpartum
  • Exogenous estrogen (OCP, HRT)
  • Acute medical illness (pneumonia, CHF)
  • Central venous catheter or pacemaker
  • Long-haul travel (>4 h)

Persistent (Unprovoked)​

Older age (strongest single factor), active cancer, obesity, antiphospholipid syndrome, personal / family VTE history, autoimmune or chronic inflammatory disease, hypertension, metabolic syndrome.[1][6][14]

Inherited Thrombophilias​

  • Factor V Leiden (3–7% in Europeans)
  • Prothrombin 20210G→A (1–2%)
  • Antithrombin, protein C, protein S deficiency
  • Non-O blood group

Thrombophilia testing has limited relevance for long-term VTE management — inherited factors only modestly predict recurrence, and results rarely alter anticoagulation duration.[6]

Smoking is not associated with higher VTE rates.[1]

Complications and Prognosis​

Acute Mortality​

  • Overall ~20% of PE patients die within 90 days, though PE is often not the primary cause (coexistent cancer, sepsis).[12]
  • 30-day mortality: low-risk <1%, intermediate-risk 2–15%, high-risk ~20%.[1][2]
  • Medicare all-cause mortality after PE: 9.1% at 30 days, 19.6% at 6 months.[2]

Post-PE Syndrome​

Affects ~50% of survivors at 1 year.[1][12]

  • Reduced exercise tolerance
  • Functional limitation
  • Reduced quality of life
  • Psychological distress

Chronic Thromboembolic Pulmonary Hypertension (CTEPH)​

  • Incidence: 1–4% of PE patients.[1]
  • Mean PAP >20 mmHg with perfusion defect on imaging at ≥3 months after PE.
  • Untreated mortality: 25–30% at 3 years.
  • Risk factors: prior PE (OR 19), younger age, larger perfusion defect, idiopathic PE.
  • Pulmonary thromboendarterectomy is potentially curative in anatomically suitable patients.

Follow-Up​

Every PE survivor warrants follow-up at ~3–6 months for:

  • Residual dyspnea or functional limitation (screen for CTEPH — echo, V/Q)
  • Anticoagulation duration decision (provoked vs unprovoked)
  • Bleeding complications of anticoagulation
  • Recurrent VTE monitoring

References​

1. Freund Y, Cohen-Aubart F, Bloom B. "Acute Pulmonary Embolism: A Review." JAMA. 2022;328(13):1336–1345. doi:10.1001/jama.2022.16815

2. Goldberg JB, Giri J, Kobayashi T, et al. "Surgical Management and Mechanical Circulatory Support in High-Risk Pulmonary Embolisms — AHA Scientific Statement." Circulation. 2023;147(9):e628–e647. doi:10.1161/CIR.0000000000001117

3. Creager MA, Barnes GD, Giri J, et al. "2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults." Circulation. 2026. doi:10.1161/CIR.0000000000001415

4. Creager MA, Barnes GD, Giri J, et al. "2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults." J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2025.11.005

5. Khan F, Tritschler T, Kahn SR, Rodger MA. "Venous Thromboembolism." Lancet. 2021;398(10294):64–77. doi:10.1016/S0140-6736(20)32658-1

6. Di Nisio M, van Es N, Büller HR. "Deep Vein Thrombosis and Pulmonary Embolism." Lancet. 2016;388(10063):3060–3073. doi:10.1016/S0140-6736(16)30514-1

7. Crawford F, Andras A, Welch K, et al. "D-Dimer Test for Excluding the Diagnosis of Pulmonary Embolism." Cochrane Database Syst Rev. 2016;(8):CD010864. doi:10.1002/14651858.CD010864.pub2

8. Kearon C, de Wit K, Parpia S, et al. "Diagnosis of Pulmonary Embolism With D-Dimer Adjusted to Clinical Probability." N Engl J Med. 2019;381(22):2125–2134. doi:10.1056/NEJMoa1909159

9. Weitz JI, Fredenburgh JC, Eikelboom JW. "A Test in Context: D-Dimer." J Am Coll Cardiol. 2017;70(19):2411–2420. doi:10.1016/j.jacc.2017.09.024

10. Zuin M, Bikdeli B, Ballard-Hernandez J, et al. "International Clinical Practice Guideline Recommendations for Acute Pulmonary Embolism: Harmony, Dissonance, and Silence." J Am Coll Cardiol. 2024;84(16):1561–1577. doi:10.1016/j.jacc.2024.07.044

11. Falster C, Hellfritzsch M, Gaist TA, et al. "Comparison of International Guideline Recommendations for the Diagnosis of Pulmonary Embolism." Lancet Haematol. 2023;10(11):e922–e935. doi:10.1016/S2352-3026(23)00181-3

12. Kahn SR, de Wit K. "Pulmonary Embolism." N Engl J Med. 2022;387(1):45–57. doi:10.1056/NEJMcp2116489

13. FDA Orange Book.

14. Goldhaber SZ, Bounameaux H. "Pulmonary Embolism and Deep Vein Thrombosis." Lancet. 2012;379(9828):1835–46. doi:10.1016/S0140-6736(11)61904-1